Runtime: 106m 29s | Release date: 2013
In the compelling follow-up to the internationally award-winning documentary,'Burzynski: the Movie', Part II explores the current status of Antineoplastons' clinical testing sanctioned by the United States Food & Drug Administration and features a modern story of the struggling journeys of cancer patients being treated today at the Burzynski Clinic in Houston, Texas.
For most patients undergoing Burzynski's treatment, their advanced cancer itself runs secondary to the constant barrage of skepticism coming not only from their local oncologists, but also from friends and family who feel their loved ones are making suspect treatment decisions - even though mainstream oncology has already left many for dead.
As the story unfolds, you will observe a real-time change of hearts and minds from many of these doctors and families. Unlike the first documentary, Part II showcases interviews with board-certified oncologists, surgeons and neurosurgeons who witnessed patients leave their care, soon to return in great health after opting for the Burzynski Clinic.
Since the mapping of the Cancer Genome, Burzynski has pioneered an expansion of his therapy, which he calls "Personalized Gene-Targeted Cancer Therapy", where each patient's Genomic Cancer Atlas is mapped and a treatment regimen is personally tailored for each individual patient - vs. the conveyor belt, "one-size-fits-all" approach that current oncology adheres to.
Due to the slow-moving, bureaucratic obstacles enforced on Antineoplastons by America's FDA, this new, expanded, "personalized gene-targeted" direction has allowed more patients (who are denied access to Antineoplastons) to benefit from Burzynski's practice in ways never before thought possible. And yet still with similar resistance and controversy endured by Burzynski's Antineoplaston therapy.
The film also takes you to Kurume University in Fukuoka, Japan where independently designed studies of Antineoplastons have been underway for 27 years without Dr. Burzynski's (the inventor's) involvement or supervision. Learn how this team of Japanese pathologists, oncologists and surgeons have studied these anti-cancer compounds using their own methodologies -resulting in the first ever, independently-run, randomized, controlled clinical trials.
Laura Fay Hymas